Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the must-buy penny stocks to invest in. On August 18, Piper Sandler reiterated its Overweight rating and $12.00 price target for Compass Therapeutics, citing strong performance and promising clinical developments. The stock has surged 131% over the past year, reflecting investor confidence in the company’s oncology pipeline.

The COMPANION-002 trial’s secondary endpoint analysis is delayed to Q1 2026 due to slower survival events in second-line biliary tract cancer. Piper Sandler sees this as a possible positive, noting that nearly 50% crossover to treatment may boost tovecimig’s survival data.

Compass expects full CTX-8371 data in Q4 2025, boosting its pipeline momentum. Backed by a solid balance sheet and progressing trials, the company is well-positioned for ongoing growth in oncology.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a U.S.-based clinical-stage biopharmaceutical company focused on oncology. It develops antibody-based therapies, with lead candidates like tovecimig—a bispecific antibody targeting DLL4 and VEGF pathways—aimed at treating aggressive cancers.

READ NEXT: 6 Best Railroad Stocks to Buy Right Now and 11 Best Very Cheap Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.